Research programme: huntingtin decoy peptides - Massachusetts Institute of TechnologyAlternative Names: Huntingtin decoy peptides research programme - Massachusetts Institute of Technology
Latest Information Update: 22 Jan 2003
At a glance
- Originator Nonindustrial source
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 01 May 2001 Preclinical development for Huntington's disease in USA (Unknown route)